19 December 2022 in Journal of the American Pharmacists Association
26 June 2025 in Journal of Pharmacy Practice
Background: Evidence supports the safe administration of levetiracetam as a rapid intravenous push (IVP) in patients experiencing breakthrough seizures or status epilepticus. Use of this route of administration may decrease morbidity and mortality by reducing time to medication delivery. Though this practice has become increasingly common in adults, the safety of IVP levetiracetam in pediatric patients is not well documented. Objective: To evaluate the safety of IVP levetiracetam in pediatric patients. Methods: Patients who received IV piggyback (IVPB) or IVP levetiracetam and were between the ages of 12 months and 18 years old were eligible for inclusion. Medication regimen data recorded includes the dose of levetiracetam, number of doses administered, and total days of administration. Additionally, time points related to order entry, pharmacist verification, and dose administration was recorded. Safety endpoints included rates of bradycardia, hypotension, behavioral changes, and cutaneous drug reactions. Descriptive and inferential statistical analysis was performed using SPSS software. Results: This study showed IVP levetiracetam has a similar rate of adverse effects when compared to IVPB levetiracetam in patients over the age of one (5.5% vs 7.5%, P = 0.3589). In addition, there was improvement in the time to administration of levetiracetam (50 min in the IVPB group and 23 min in the IVP group [ P = .0008]). Conclusion: Pediatric patients who received undiluted (100 mg/mL) levetiracetam IVP over 5 min had a similar adverse event incidence when compared to those who received the anti-epileptic drug (AED) as an IVPB. This evaluation demonstrated that doses up to 1500 mg of undiluted IVP levetiracetam is safe for pediatric patients.
20 July 2025 in Journal of Pain & Palliative Care Pharmacotherapy
Pain management is a critical challenge in healthcare as acute and chronic pain affect millions of individuals globally. Opioid-based therapies that were once considered the traditional treatment methods are facing scrutiny due to their limitations and risks, due to which it is evident that an equally effective alternative pain management approach is necessary. Ketamine is a promising solution. Ketamine acts as an NMDA (N-methyl-D-aspartate) receptor antagonist, and modulates pain pathways at central and peripheral levels, which enables it to address complex pain mechanisms that opioids cannot adequately target. It is a valuable option for patients who are opioid refractory, intolerant, or have insufficient pain relief from standard therapies. While traditionally used in intensive care units (ICUs), ketamine use has been expanded to general inpatient floors at our institution. This article will present a model for implementing a low-dose ketamine protocol for pain management in a community hospital setting, using our experience as a prototype. It will highlight ketamine's pharmacological advantages, safety considerations, and the staff education, logistics, and collaboration necessary for implementation. By pioneering this model in our county, our goal is to provide a model for other community hospitals to adopt.